Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche breast cancer drug at center of UK pricing row

A Roche drug that can prolong the lives of some women with advanced breast cancer has been plunged back into the center of a drug pricing row after Britain’s health cost agency declared that it is still too expensive. The stand-off shows how the price of medicines is as pressing and emotive an issue in […]

Read More »

FDA clears Merrimack’s pancreatic cancer drug with warning

The U.S. Food and Drug Administration on Thursday approved Merrimack Pharmaceutical Inc’s pancreatic cancer drug, Onivyde, with a severe safety warning. The company’s shares fell as much as 28 percent to a 13-month low of $7.27 in afternoon trade before halving the losses. Onivyde, in combination with chemotherapy treatments 5-fluorouracil and leucovorin, aims to treat […]

Read More »

ImmunoGen, Roche gastric cancer drug fails study

ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study. ImmunoGen entered into a royalty purchase agreement with Roche for Kadcyla this year. Kadcyla, approved in 2013 for the treatment of late-stage breast cancer, was being tested as a second-line treatment […]

Read More »

23andMe launches new consumer test service to check for genetic disorders

Genetics company 23andMe announced the launch of a new consumer genetic test service on Wednesday that will show whether an individual carries genes associated with 36 different disorders, such as cystic fibrosis. The launch is a major step for the company, which in 2013 was ordered by the Food and Drug Administration to stop selling […]

Read More »

American Cancer Society eases mammogram recommendations

(Reuters Health) – In a major shift, the American Cancer Society is recommending that women at average risk of breast cancer get annual mammograms starting at age 45 rather than at age 40, and that women 55 and older scale back screening to every other year. The new guidelines, published on Tuesday in JAMA, fall […]

Read More »

Call for Britain to over-ride patents on Roche cancer drug

A group of patients and campaigners has called on Britain’s health minister to over-ride patents protecting Roche’s expensive breast cancer drug Kadcyla to allow for the import or manufacture of cut-price copies.   The move shows the growing pricing pressure on drug companies on both sides of the Atlantic, especially in the field of cancer […]

Read More »

Novartis launches portfolio for low and low-middle-income countries

Novartis AG launched a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries, the drugmaker said in a statement on Thursday.   The Basel-based company said ‘Novartis Access’ will be launched first in Kenya, Ethiopia and Vietnam, with expansion to eventually include 30 countries. Novartis said the portfolio addresses cardiovascular diseases, […]

Read More »

Veritas Genetics Receives European CE Mark Approval for myBRCA Genetic Test for Hereditary Breast and Ovarian Cancer

BOSTON, Aug. 24, 2015 /PRNewswire/ — Boston-based Veritas Genetics, a pioneer in accessible genetic screening for disease prevention and early detection, received its first European CE mark approval for the company’s hereditary breast and ovarian cancer genetic screening test, myBRCA. Veritas introduced myBRCA, which sequences BRCA1 and BRCA2 genes using proprietary gene-targeting technology and Next Generation […]

Read More »

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for Monotherapy or Combination Therapy With Standard of Care Oncology Treatments; Transaction Price of $410 Million Upfront, Up to $160 Million in Milestones and Mid-Single Digit Royalties SAN FRANCISCO, […]

Read More »

BioMarin Sells Phase III Breast Cancer Drug to Medivation for $570 Million

San Francisco-based Medivation, Inc. (MDVN), and San Rafael, Calif.-based BioMarin Pharmaceutical Inc. (BMRN) announced today that they have signed a deal for Medivation to buy all worldwide rights to talazoparib, formerly called BMN 673, for breast cancer treatment. Medivation will take over all research, development, regulatory and commercial activities.   Medivation will pay BioMarin $410 […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom